A row over a client has led to a split between Ogilvy PR Worldwide and Magellan Medical Communications, the healthcare agency it bought only one year ago.
Founder and MD of Magellan, Tom Delaney, has repurchased the company for an undisclosed sum. He takes one member of Ogilvy staff, account director Tara Mistry.
The split occurred after Ogilvy asked Delaney, who had become MD of Ogilvy's health and medical PR, to give up his account with Japanese drug firm Takeda, a relationship that began in March 1999.
Ogilvy was seeking to transfer its New York-based account with Novartis, including the promotion of its diabetes drug Starlix, to London, which would have created a conflict of interest with Takeda.
Delaney has been replaced by Charles Butler, who transferred from Ogilvy's New York office last year to become a director in London.
Ogilvy's London office now handles PR for Starlix and other Novartis products: Comtan, a Parkinson's disease drug and Exelon, used in the treatment of Alzheimer's.